Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (8 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 17 Oct 2016 – 20 Aug 2026, limited by BANDHAN BSE Sensex ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | BANDHAN BSE Sensex ETF | Nifty 50 |
|---|---|---|
| 17 Oct 2016 | ₹100.00 | ₹100.00 |
| 13 Aug 2017 | ₹114.77 | ₹113.97 |
| 08 Jun 2018 | ₹130.84 | ₹126.37 |
| 04 Apr 2019 | ₹144.11 | ₹136.12 |
| 28 Jan 2020 | ₹153.87 | ₹141.49 |
| 23 Nov 2020 | ₹167.20 | ₹151.71 |
| 18 Sep 2021 | ₹224.43 | ₹206.39 |
| 15 Jul 2022 | ₹205.92 | ₹188.36 |
| 10 May 2023 | ₹237.97 | ₹214.96 |
| 05 Mar 2024 | ₹285.73 | ₹262.39 |
| 29 Dec 2024 | ₹307.35 | ₹279.49 |
| 25 Oct 2025 | ₹331.32 | ₹302.75 |
| 20 Aug 2026 | ₹307.17 | ₹284.40 |
| Metric | Bandhan · Regular NAV ₹844.18 Very High risk ★☆☆☆☆ | Category median Other ETFs · 8 funds |
|---|---|---|
| -4.63% | +5.05% | |
| +6.89% | +8.99% | |
| +7.85% | +9.22% | |
| — | — | |
| +12.08% | +12.22% | |
| +5.80% | — | |
| +13.83% | +14.04% | |
| +14.63% | +14.90% | |
| — | — | |
| Risk | ||
| 13.15% | 14.32% | |
| 0.03 | 0.19 | |
| 0.04 | 0.26 | |
| -37.30% | -37.51% | |
| Nifty 50 | — | |
| -0.94% | +1.06% | |
| 0.98 | 1.00 | |
| 98.1% | 102.5% | |
| 103.8% | 97.8% | |
| 0.32% | 0.29% | |
| ₹1.16Cr | ₹205.35Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Abhishek Jain | — | |
| 17 Oct 2016 | — | |
| 30 | — | |
| 63.4% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.